Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance

~ Amryt now has three approved commercial products and a robust clinical pipeline ~ 35.9% YoY revenue growth in Q2 to $62.8M ~ 6th consecutive quarter of positive EBITDA generation ~ Cash increased to $142.9M at June 30 from $118.6M at March 31 ~ Oleogel-S10 NDA accepted by the FDA, Priority Review granted; target PDUFA date set for November 30, 2021 ~ Raising FY 2021 revenue guidance to $210M - $215M, representing 15-18% YoY growth